EZH2 and neoplasm: Of note, EZH2 inhibitors in combination with CAR-T therapy boost the anti-tumor activity of CAR-T in Ewing sarcoma by reducing H3K27me3 mark and inducing the surface expression of GD2, a stemness marker in tumor cells (Kailayangiri et al., 2019).